FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Breckenridge Pharmaceutical Duloxetine Delayed-Release Capsules Recall

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Ma…

Breckenridge Pharmaceutical, Inc. · Berkeley Heights, NJ

Risk level
Class II
Reported by FDA
Aug 20, 2025
Recall ID
D-0580-2025
Check your lot numberHow we source this data

Summary

Breckenridge Pharmaceutical recalled Duloxetine Delayed-Release Capsules starting Jul 25, 2025. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0580-2025 on Aug 20, 2025. Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Product description

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC 82009-032-10

Lot numbers, UPCs & expiration codes

Lot 240539C, Exp 1/31/2027

Where it was sold

NJ, AZ, IN

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0580-2025
Classification
Class II
Status
Ongoing
Recall initiated
Jul 25, 2025
FDA report date
Aug 20, 2025
Quantity
1,856 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Breckenridge Pharmaceutical, Inc.

Original FDA data

Every field from FDA enforcement report D-0580-2025, exactly as published.

Show all FDA fields
City
Berkeley Heights
State
NJ
Status
Ongoing
Country
United States
Event ID
97336
Address
200 Connell Dr Ste 4200
Code information
Lot 240539C, Exp 1/31/2027
Postal code
07922-2805
Report date
Aug 20, 2025
Product type
Drugs
Recall number
D-0580-2025
Classification
Class II
Recalling firm
Breckenridge Pharmaceutical, Inc.
Product quantity
1,856 bottles
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC 82009-032-10
Distribution pattern
NJ, AZ, IN
Recall initiation date
Jul 25, 2025
Initial firm notification
Letter
Center classification date
Aug 12, 2025

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0580-2025, published Aug 20, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls